Understanding Why Skyland PIMS Was Selected – Novavax

Hear about a late-stage biotechnology company with vaccine candidates that are genetically engineered using three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. Driven by its COVID-19 vaccine development and manufacturing data management complexities, the company wanted to harden its data infrastructure, discontinue wide-scale use of Excel for batch/process/product data management, and accelerate data sharing among a large external network.

Learn how the keys to success helped the biotechnology company achieve its goals.